Bullboard - Stock Discussion Forum Bioxytran Inc BIXT

Healthcare Biotechnology

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes... see more

Add To Watchlist

OTCQB:BIXT - Post Discussion

Bioxytran Inc > AVISE ANALYTICS REINITIATES COVERAGE ON BIOXYTRAN, INC.

View:

Post by AviseAnalytics on Nov 22, 2022 1:32pm

AVISE ANALYTICS REINITIATES COVERAGE ON BIOXYTRAN, INC.

$ BIXT

We reinitiate our coverage on Bioxytran, Inc. (OTCQB: BIXT) with a fair valuation of $2.71 per share. Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, ProLectin-M, is a new class of antiviral drugs designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. It is also developing BXT-25, a glycopolymer that acts as an anti-necrosis drug by carrying oxygen to tissues even when blood flow is blocked and can reverse hypoxia (oxygen deficiency).

The full research report is available here.

https://www.nasdaq.com/press-release/bioxytran-inc.-announces-the-reinitiation-of-coverage-of-its-stock-by-avise-analytics

106